IL37 and neoplasm: Systemic IL-23 application did not induce intense toxicity as has been seen with IL-12 43; however, oncolytic vaccinia virus can replicate robustly in the TME and accumulate transgene products in a short time, especially in the late-stage tumors with high tumor volume, and thus, the possible toxicity might be considered.